Publications by authors named "K Kamikozuru"
Background And Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn's disease (CD).
Methods: Patients with moderately to severely active CD and clinical response to 12-week risankizumab induction were rerandomized to continued therapy or drug withdrawal in the phase 3 FORTIFY maintenance trial. Incidence rates (events/100 person-years) of CD-related hospitalization and surgery, and the composite of both, through 52 weeks of maintenance were compared between patients achieving vs not achieving predefined endoscopic outcomes following induction.
Few studies have compared the efficacy and safety of Janus kinase (JAK) inhibitors in patients with ulcerative colitis (UC). We compared the real-world effectiveness and safety of tofacitinib (TOF) and filgotinib (FIL) as induction therapy for UC by propensity score-matching analysis. We enrolled 230 patients with active UC who received either TOF (n = 197) or FIL (n = 33) as induction therapy.
View Article and Find Full Text PDFArticle Synopsis
- Cronkhite-Canada syndrome (CCS) is a rare gastrointestinal disorder characterized by taste abnormalities, observed in over 80% of cases, along with various ectodermal issues like nail atrophy and hair loss.
- Ten diagnosed patients underwent assessments for taste function and other symptoms before and after treatment, revealing significant improvements in taste, especially in the anterior tongue.
- The study shows that taste function tests are effective in measuring treatment outcomes, as patients experienced both symptom relief and improved taste function within three months post-treatment.
Background: Real-world data on tofacitinib (TOF) covering a period of more than 1 year for a sufficient number of Asian patients with ulcerative colitis (UC) are scarce.
Aim: To investigate the long-term efficacy and safety of TOF treatment for UC, including clinical issues.
Methods: We performed a retrospective single-center observational analysis of 111 UC patients administered TOF at Hyogo Medical University as a tertiary inflammatory bowel disease center.
[Advances in biomarkers and clinical applications in inflammatory bowel disease].
Nihon Shokakibyo Gakkai Zasshi
November 2023